Nyagwange J

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns.Lambisia AW Nyiro J Githinji G Katama EN Moraa E Mwita JM Mutunga M Maina G Bejon P Phan MVT Cotten M Dellicour S Ochola-Oyier LI Sande C Holmes EC Nyagwange J Agoti CN
Open Forum Infect Dis, (2026). 13:ofag084

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.Waweru G Nyakundi R Kutima B Owuor S Konyino G Gitonga J Lugano D Maina A Musyoki J Ochola L Omondi M Kariuki CK Ogongo P Mwachari C Shee F Agoti C Sande C Uyoga S Kagucia E Agweyu A Bejon P Scott JAG Warimwe GM Ochola-Oyier LI Nyagwange J
Viruses, (2025). 17:

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.Lambisia AW Katama EN Moraa E Mwita JM Gallagher K Mutunga M Nyale E Omungala J Mwanga M Murunga N Nyiro J Nyagwange J Sande C Bejon P Githinji G Dellicour S Phan MVT Cotten M Ochola-Oyier LI Holmes EC Agoti CN
BMC Glob Public Health, (2025). 3:80

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.Kagucia EW Voller S Ziraba AK Bigogo G Munywoki PK Makobu K Nokes DJ Nyagwange J Orlendo C Akech D Sigilai A Onyango C Juma B Herman-Roloff A Munyua P Apondi C Lidechi S Audi A Ouma A Aol G Misore T Nasimiyu C Onyango D Lo T Kasera K Jalang'o R Kingwara L Adetifa I Etyang AO Warimwe G Agweyu A Scott JAG
Gates Open Res, (2025). 8:60

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho J Sein Y Sayed S Shah R Mwai K Saleh M Wanjiku P Mwacharo J Nyagwange J Karanja H Kutima B Gitonga JN Mugo D Karanu A Moranga L Oluoch V Shah J Mutiso J Mburu A Nneka Z Betti P Usyu Mutinda W Abdi AI Bejon P Ochola-Oyier LI Warimwe GM Nduati EW Ndungu FM
Wellcome Open Res, (2025). 8:350

Comparative performance of the InBios SCoV-2 Detect (TM) IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.Kutima B Kagucia EW Mwai K Kimani M Sigilai A Mugo D Karanja H Gitonga JN Karani A Akech D Toroitich M Karia B Tuju J Ziraba AK Bigogo G Ochieng C Onyango C Lidechi S Munywoki PK Uyoga S Adetifa IMO Oyier LIO Bejon P Scott JAG Agweyu A Warimwe GM Nyagwange J Kenya Sars-CoV-Serology Consortium
Wellcome Open Res, (2024). 9:349

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano D Kutima B Kimani M Sigilai A Gitonga J Karani A Akech D Karia B Ziraba AK Maina A Lambisia A Omuoyo D Mugo D Lucinde R Owuor S Konyino G Newman J Bailey D Nduati E Githinji G Agoti CN Bejon P Scott JAG Agweyu A Kagucia W Warimwe GM Sande C Ochola-Oyier LI Nyagwange J
BMC Infect Dis, (2024). 24:1474

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M Sang S Orindi B Njau I Karanja H Kamau N Gitonga JN Mugo D Wright D Nyagwange J Kutima B Omuoyo D Mwatasa M Ngetsa C Agoti C Cheruiyot S Nyaguara A Munene M Mturi N Oloo E Ochola-Oyier L Mumba N Mauncho C Namayi R Davies A Tsofa B Nduati EW Aliyan N Kasera K Etyang A Boyd A Hill A Gilbert S Douglas A Pollard A Bejon P Lambe T Warimwe G COVVaccine Trial Group
Wellcome Open Res, (2023). 8:182

Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.Gallagher KE Nyiro J Agoti CN Maitha E Nyagwange J Karani A Bottomley C Murunga N Githinji G Mutunga M Ochola-Oyier LI Kombe I Nyaguara A Kagucia EW Warimwe G Agweyu A Tsofa B Bejon P Scott JAG Nokes DJ
Influenza Other Respir Viruses, (2023). 17:e13185

SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.Kagucia EW Ziraba AK Nyagwange J Kutima B Kimani M Akech D Ng'oda M Sigilai A Mugo D Karanja H Gitonga J Karani A Toroitich M Karia B Otiende M Njeri A Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Voller S Ochola-Oyier LI Bottomley C Nyaguara A Munywoki PK Bigogo G Maitha E Uyoga S Gallagher KE Etyang AO Barasa E Mwangangi J Bejon P Adetifa IMO Warimwe GM Scott JAG Agweyu A
Influenza Other Respir Viruses, (2023). 17:e13173

A Customizable Suite of Methods to Sequence and Annotate Cattle Antibodies.Ramirez Valdez K Nzau B Dorey-Robinson D Jarman M Nyagwange J Schwartz JC Freimanis G Steyn AW Warimwe GM Morrison LJ Mwangi W Charleston B Bonnet-Di Placido M Hammond JA
Vaccines (Basel), (2023). 11:

Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.Nyagwange J Kutima B Mwai K Karanja HK Gitonga JN Mugo D Sein Y Wright D Omuoyo DO Nyiro JU Tuju J Nokes DJ Agweyu A Bejon P Ochola-Oyier LI Scott JAG Lambe T Nduati E Agoti C Warimwe GM
Int J Infect Dis, (2023). 127:11-16

SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.Etyang AO Adetifa I Omore R Misore T Ziraba AK Ng'oda MA Gitau E Gitonga J Mugo D Kutima B Karanja H Toroitich M Nyagwange J Tuju J Wanjiku P Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Akech D Sigilai A Karia B Karani A Voller S Agoti CN Ochola-Oyier LI Otiende M Bottomley C Nyaguara A Uyoga S Gallagher K Kagucia EW Onyango D Tsofa B Mwangangi J Maitha E Barasa E Bejon P Warimwe GM Scott JAG Agweyu A
PLOS Glob Public Health, (2022). 2:e0000883

Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21.Lucinde RK Mugo D Bottomley C Karani A Gardiner E Aziza R Gitonga JN Karanja H Nyagwange J Tuju J Wanjiku P Nzomo E Kamuri E Thuranira K Agunda S Nyutu G Etyang AO Adetifa IMO Kagucia E Uyoga S Otiende M Otieno E Ndwiga L Agoti CN Aman RA Mwangangi M Amoth P Kasera K Nyaguara A Ng'ang'a W Ochola LB Namdala E Gaunya O Okuku R Barasa E Bejon P Tsofa B Ochola-Oyier LI Warimwe GM Agweyu A Scott JAG Gallagher KE
PLoS One, (2022). 17:e0265478

Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya.Nyagwange J Ndwiga L Muteru K Wamae K Tuju J Testing Team C Kutima B Gitonga J Karanja H Mugo D Kasera K Amoth P Murunga N Babu L Otieno E Githinji G Nokes DJ Tsofa B Orindi B Barasa E Warimwe G Agoti CN Bejon P Ochola-Oyier LI
Wellcome Open Res, (2022). 7:69

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations.Nyagwange J Kutima B Mwai K Karanja HK Gitonga JN Mugo D Uyoga S Tuju J Ochola-Oyier LI Ndungu F Bejon P Agweyu A Adetifa IMO Scott JAG Warimwe GM
J Clin Virol, (2022). 146:105061

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.Etyang AO Lucinde R Karanja H Kalu C Mugo D Nyagwange J Gitonga J Tuju J Wanjiku P Karani A Mutua S Maroko H Nzomo E Maitha E Kamuri E Kaugiria T Weru J Ochola LB Kilimo N Charo S Emukule N Moracha W Mukabi D Okuku R Ogutu M Angujo B Otiende M Bottomley C Otieno E Ndwiga L Nyaguara A Voller S Agoti CN Nokes DJ Ochola-Oyier LI Aman R Amoth P Mwangangi M Kasera K Ng'ang'a W Adetifa IMO Wangeci Kagucia E Gallagher K Uyoga S Tsofa B Barasa E Bejon P Scott JAG Agweyu A Warimwe GM
Clin Infect Dis, (2022). 74:288-293

Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels.Bottomley C Otiende M Uyoga S Gallagher K Kagucia EW Etyang AO Mugo D Gitonga J Karanja H Nyagwange J Adetifa IMO Agweyu A Nokes DJ Warimwe GM Scott JAG
Nat Commun, (2021). 12:6196

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.Kagucia EW Gitonga JN Kalu C Ochomo E Ochieng B Kuya N Karani A Nyagwange J Karia B Mugo D Karanja HK Tuju J Mutiso A Maroko H Okubi L Maitha E Ajuck H Mukabi D Moracha W Bulimu D Andanje N Aman R Mwangangi M Amoth P Kasera K Ng'ang'a W Nyaguara A Voller S Otiende M Bottomley C Agoti CN Ochola-Oyier LI Adetifa IMO Etyang AO Gallagher KE Uyoga S Barasa E Bejon P Tsofa B Agweyu A Warimwe GM Scott JAG Magarini Sub-County Tda Sars-CoV-2 Serosurveillance Team The Busia County TDASars-CoV-Serosurveillance Team
Open Forum Infect Dis, (2021). 8:ofab314

COVID-19 transmission dynamics underlying epidemic waves in Kenya.Brand SPC Ojal J Aziza R Were V Okiro EA Kombe IK Mburu C Ogero M Agweyu A Warimwe GM Nyagwange J Karanja H Gitonga JN Mugo D Uyoga S Adetifa IMO Scott JAG Otieno E Murunga N Otiende M Ochola-Oyier LI Agoti CN Githinji G Kasera K Amoth P Mwangangi M Aman R Ng'ang'a W Tsofa B Bejon P Keeling MJ Nokes DJ Barasa E
Science, (2021). 374:989-994